Scholarlink

<p>Acute respiratory distress syndrome (ARDS) secondary to viral pneumonias, predominantly COVID-19 but also influenza and adenovirus, remains a major ICU mortality driver, with rates exceeding 40%. Chronic high-altitude adaptation (≥ 2,500&#xa0;m) modifies human pulmonary physiology through hypoxia-inducible factor (HIF-1α/2α) stabilization, ACE2 downregulation, enhanced capillary recruitment, and anti-inflammatory shifts, potentially reducing ARDS severity. Across published observational studies, findings remain heterogeneous; however, several cohorts have reported lower mortality at moderate-to-high altitude (approximately 30–50% in some reports), along with proposed altitude-appropriate SpO₂ targets (89–93%) and alternative interpretations of oxygenation indices (e.g., barometric pressure–adjusted P/F ratios). Protection is strongest in younger, comorbidity-free patients, but attenuates in diabetics/hypertensives. In this perspective, we critically examine the evidence on how altitude may influence the clinical course and survival of critically ill patients, exploring potential pulmonary adaptive mechanisms and reflecting on their implications for monitoring and management in intensive care units.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Chronic hypoxia adaptation at high altitude: a perspective on Its potential role in mortality in viral pneumonia-associated ARDS and implications for personalized critical care

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月25日

查看全文
  • Esteban Ortiz-Prado,
  • María Paz Cadena-Padilla,
  • Jorge Luis Vélez-Páez,
  • Jorge Vasconez-Gonzalez,
  • Juan S. Izquierdo-Condoy,
  • Micaela Vergara,
  • Ginés Viscor

摘要

Acute respiratory distress syndrome (ARDS) secondary to viral pneumonias, predominantly COVID-19 but also influenza and adenovirus, remains a major ICU mortality driver, with rates exceeding 40%. Chronic high-altitude adaptation (≥ 2,500 m) modifies human pulmonary physiology through hypoxia-inducible factor (HIF-1α/2α) stabilization, ACE2 downregulation, enhanced capillary recruitment, and anti-inflammatory shifts, potentially reducing ARDS severity. Across published observational studies, findings remain heterogeneous; however, several cohorts have reported lower mortality at moderate-to-high altitude (approximately 30–50% in some reports), along with proposed altitude-appropriate SpO₂ targets (89–93%) and alternative interpretations of oxygenation indices (e.g., barometric pressure–adjusted P/F ratios). Protection is strongest in younger, comorbidity-free patients, but attenuates in diabetics/hypertensives. In this perspective, we critically examine the evidence on how altitude may influence the clinical course and survival of critically ill patients, exploring potential pulmonary adaptive mechanisms and reflecting on their implications for monitoring and management in intensive care units.